Walvax presents safety and non-inferior immunogenicity results of its MPV ACYW135 compared with Menactra® at Leading Scientific Conferences
(Nov 2, 2023, Kunming) Walvax Biotechnology Co., Ltd. (“Walvax”, 300142.SZ) announces today representatives from Walvax presented safety and non-inferior immunogenicity results of its quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) from a phase 4 clinical study conducted at the Centre pour le Développement des Vaccins du Mali (CVD-Mali), in Bamako, Mali during December 2020 to July 2021, at 2 leading scientific conferences during the fourth quarter of 2023.
During the 2023 International Society for Vaccines (ISV) Annual Congress taking place October 22 – 24, 2023 in Lausanne, Switzerland, Walvax displayed a poster titled “Safety and Immunogenicity of Quadrivalent Meningococcal Polysaccharide Vaccine MPV ACYW135) Compared with Quadrivalent Meningococcal Conjugate Vaccine (Menactra®) in Malian Children”. Representatives from Walvax attended the poster session and academic seminars during the congress, communicated with academic and industry representatives and exchanged ideas regarding prevention of infectious diseases and development of vaccines.
At the virtual conference platform of Meningitis Research Foundation Conference 2023, Walvax has its poster titled “Safety and Immunogenicity of Quadrivalent Meningococcal Polysaccharide Vaccine MPV ACYW135) Compared with Quadrivalent Meningococcal Conjugate Vaccine (Menactra®) in Malian Children” presented under the topic “Prevention and Epidemic Control”, along with other posters discussing various aspects in controlling meningitis and septicaemia.
Please see key points regarding the phase 4 clinical study in press released on July 5, link here
About International Society for Vaccines (ISV)
The International Society for Vaccines is an organization that engages, supports, and sustains the professional goals of a diverse membership in all areas relevant to vaccines and immunotherapeutics. The ISV is a global not-for-profit organization that aims to encourage, establish, and promote the development and use of vaccines to prevent and control infectious and non-infectious diseases in humans and animals.
About Meningitis Research Foundation (MRF)
Meningitis Research Foundation is a leading international charity, working to defeat meningitis and septicaemia since 1989. In 2021, it strengthened its long-standing collaboration with the global member network, Confederation of Meningitis Organisations (CoMO), becoming one organisation.
About the Group ACYW135 Meningococcal Polysaccharide Vaccine
Group ACYW135 Meningococcal Polysaccharide Vaccine (MPV ACYW135) is a lyophilized vaccine of purified meningococcal capsular polysaccharides of groups A, C, Y and W135 Neisseria meningitides (N. meningitides), developed by Yuxi Walvax, one subsidiary of Walvax Biotechnology Co., Ltd. The MPV ACYW135 is supplied as a single dose vial of lyophilized powder, with corresponding single dose of diluent. Each dose of 0.5 mL contains 50 μg each of polysaccharide for serogroup A, C, Y and W135 as active ingredients. MPV ACYW135 vaccine is indicated for active immunization to prevent invasive meningococcal diseases caused by N. meningitidis serogroups A, C, Y and W135 in individuals aged 2 years and above who are at increased risk for meningococcal diseases as a single-dose regimen. MPV ACYW135 vaccine should be stored and transported at 2℃ to 8℃ with protection from light (with diluent stored and transported at 2℃ to 30℃). The shelf life of the vaccine is 24 months.
About the Phase 4 Clinical Study (MPV ACYW-004)
The Phase 4 clinical study MPV ACYW-004, registered on clinicaltrials.gov (NCT04450498), designed as a single-center, observer-blind, randomized, controlled vaccine trial in healthy subjects 2 to 10 years of age, was conducted at the Centre pour le Développement des Vaccins du Mali (CVD-Mali), in Bamako, Mali during December 2020 to July 2021. A total of 260 healthy children aged from 2 to 10 years with residence in the study area were enrolled and randomized 1:1 to receive one single intramuscular injection of either Walvax MPV ACYW135 vaccine or Sanofi Pasteur Menactra®. Primary and secondary immunogenicity endpoints were assessed with blood samples taken on the day of vaccination and 30 days after vaccination. Samples were tested by serum bactericidal antibody assay using baby rabbit complement (rSBA) to A, C, Y, W meningococcal strains by the Vaccine Evaluation Unit, UK Health Security Agency, Manchester, UK. Subjects were observed for 30 minutes after vaccination for any immediate post-immunization reactions. Solicited local and systemic reactions within 6 days after vaccination as well as unsolicited adverse events between Day 1 and Day 30 after vaccination were collected by investigators through home visits or during on-site visits. Serious adverse events were collected and followed up for six months after vaccination.
Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe and efficacious quality vaccines. Headquartered in China’s southwestern city Kunming in Yunnan Province, Walvax went to IPO in 2010 (300142.SZ) and started business expansion from traditional vaccines to innovative vaccines. With the vision of dedicating to be the pride domestically and the pioneer globally in the vaccine industry, producing efficacious, quality, innovative and affordable products to protect people from the world’s deadliest diseases, Walvaxs purpose is to help everyone live a healthy life. For further information please visit https://en.walvax.com/about-us/our-company and follow us on Twitter at @WalvaxBiotech and LinkedIn.